Mark Hughes Foundation Centre for Brain Cancer Research (MHF) shared on LinkedIn:
“We were honored to stand with members of the Australian brain tumor community as Health Minister Mark Butler announced that Vorasidenib will be listed on the PBS. A truly groundbreaking moment, this is the first new treatment in 20 years for a rare brain cancer and listing it on the PBS makes it affordable and accessible to patients. This treatment option for Australians with IDH-mutant astrocytoma and oligodendroglioma targets the underlying genetic mutation that drives tumor growth, helping to slow disease progression in patients with these rare brain tumors.
We are proud to stand as a member of the Brain Tumor Alliance Australia today and every day. This outcome is testament to the power of community who came together with clinicians and researchers and got involved in clinical trials, advocated and shared their voice in huge numbers to the PBS. It’s the first of many steps into delivering better outcomes for patients with brain tumors – we are stronger together.”
Read the transcript of the press conference
You can also read: ‘Four-Arc Coplanar VMAT Emerges as a Practical Option for Hippocampal-Sparing Whole-Brain Radiotherapy‘
